Skip to main content
MGX logo

Metagenomi, Inc. Common Stock (MGX) Stock Price & Analysis

Metagenomi, Inc. Common Stock (MGX) — MoonshotScore 21/100 (Weak band), calculated Nov 22, 2026. Price $0.565 (-7.95%), as of the Nov 20, 2026 trading session; market cap $21.4M.

Educational signal · not a buy or sell recommendation · How to read this

$0.565 −$0.0488 (-7.95%) Market Cap $21.4M

Metagenomi, Inc. Common Stock · MGX · NASDAQ

Metagenomi, Inc. is a gene editing biotechnology company focused on developing novel therapeutics. The company leverages its metagenomics-derived genome editing toolbox and strategic collaborations to advance in vivo human therapeutic applications.

Price as of Nov 20, 2026

Key Statistics

21 of 100

MoonshotScore v2 · Metagenomi, Inc. Common Stock (MGX)

Weak
Business Quality Poor (15)
Financial Safety Strained (26)
Valuation Bubble (16)
Growth Durability Flat (54)
Momentum Slipping (28)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a strained balance sheet and an expensive valuation, though growth is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Bubble; Growth Durability: Flat; Momentum: Slipping.

Earnings yield is the main valuation drag relative to sector peers.

  • quarterly revenue $2M (Q3 FY2026, quarter ended Sep 30, 2026)
  • EPS beat 4 of the last 8 reports
  • Altman Z -4.53 · Piotroski F 2

Holding back: weak fundamentals, balance-sheet strain, a rich price, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for MGX (58 recorded, newest six shown)
RecordedScoreBand
20Weak
20Weak
20Weak
20Weak
20Weak
20Weak

The score moved from 20 in the stored Nov 21, 2026 snapshot to 21 in the current publication computed Nov 22, 2026 (+1); the largest pillar moves were Valuation +1. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.565
Change on the day-7.95%
52-week range$0.565 – $1.87
Market capitalisation$21.4M—
Shares traded on the day274.4K

Price & events

Other perspectives

Council score for Metagenomi, Inc. Common Stock (MGX): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Negative
Financial Safety Weak
Valuation Negative
Growth Durability Neutral
Momentum Weak

Legends Council

3 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Oct 6, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Neutral
ROE Negative
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 22, 2026, except a card that shows its own read date.

1 · What is it?

What is Metagenomi, Inc. Common Stock (MGX), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Metagenomi, Inc. Common Stock (MGX) is listed on NASDAQ. It employs 119 people and is led by Jian Irish. In Q3 FY2026 it reported revenue of $2M and net income of -$21M. The market values it at $21.4M.

2 · Latest results

What do the latest results show for Metagenomi, Inc. Common Stock (MGX)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $2M. Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Quarterly income statement — 3 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$2M-$21M-$0.56 (diluted)
Q1 FY2026$1M-$23M-$0.61 (diluted)
Q4 FY2025$4M-$23M-$0.60 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Metagenomi, Inc. Common Stock (MGX)?

Short answer · as of

What is holding it back is weak fundamentals, balance-sheet strain, a rich price, weak price trend. The distress and quality screens read Altman Z -4.53 · Piotroski F 2. Trailing ratios: ROE -75.0% · ROA -59.8% · current ratio 3.43.

Data-derived red flags

  • Listing risk — at $0.565 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -4.53 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-75.0%) — the business is not currently generating profit on shareholder capital.
5 · Peer comparison

How does Metagenomi, Inc. Common Stock compare with its peers?

Short answer

Metagenomi, Inc. Common Stock's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.09 Nov 20, 2026$462M92 5-pillar Nov 22, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$8.76 Nov 20, 2026$521M91 5-pillar Nov 22, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.90 Nov 20, 2026$245M90 5-pillar Nov 22, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$40.09 Nov 20, 2026$755M87 5-pillar Nov 22, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.47 Nov 20, 2026$83.3M82 5-pillar Nov 22, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$10.92 Nov 20, 2026$99.3M82 5-pillar Nov 22, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.57 Nov 20, 2026$155M72 5-pillar Nov 22, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.84 Nov 20, 2026$174M70 5-pillar Nov 22, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.19 Nov 20, 2026$540M68 5-pillar Nov 22, 2026
Alopexx, Inc. (ALPX) Same industry, near in market value$10.02 Nov 20, 2026$148M61 5-pillar Nov 22, 2026
AN2 Therapeutics, Inc. (ANTX) Same industry, near in market value$5.08 Nov 20, 2026$193M61 5-pillar Nov 22, 2026
Q32 Bio Inc. (QTTB) Same industry, near in market value$8.34 Nov 20, 2026$250M61 5-pillar Nov 22, 2026
Metagenomi, Inc. Common Stock (MGX) — this page$0.565$21.4M21

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held MGX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported MGX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About MGX

These answers are editorial: 1 of these 9 answers is drawn from the MGX research dossier (written May 7, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for MGX?

MGX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Metagenomi, Inc. is a gene editing biotechnology company focused on developing novel therapeutics.

Is MGX a good stock to buy?

Stock Expert AI does not rate MGX buy, sell or hold. Metagenomi, Inc. Common Stock carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the MGX stock price today?

The last price recorded for Metagenomi, Inc. Common Stock (MGX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for MGX?

The main risks for Metagenomi, Inc. include the inherent challenges of drug development, such as clinical trial failures and regulatory approval delays.

What are the key factors to evaluate for MGX?

Metagenomi, Inc. Common Stock (MGX) holds a MoonshotScore in the low range. The company can leverage this toolbox to develop its own pipeline of gene editing therapies, targeting a wide range of diseases. Not financial advice.

How frequently does MGX data refresh on this page?

MGX's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven MGX's recent stock price performance?

Metagenomi, Inc. Common Stock (MGX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary metagenomics-derived genome editing toolbox. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider MGX overvalued or undervalued right now?

Metagenomi, Inc. Common Stock (MGX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of MGX?

Fractional-share availability for Metagenomi, Inc. Common Stock (MGX) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 7, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 7 from Financial Modeling Prep (FMP), 7 with no recorded source and 3 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.